Ligosan Slow Release (Doxycycline Hyclate)

Doxycycline hyclate inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl‑tRNA. This blocks the formation of essential proteins, producing a bacteriostatic effect against the microorganisms that cause gum infection and inflammation.

The dosage of Ligosan Slow Release is determined by the prescribing clinician based on the severity of the periodontal condition, patient weight, renal function and other individual factors. Healthcare professionals set the exact amount, frequency and duration of therapy; patients should follow the prescription label precisely.

Doxycycline hyclate is classified as pregnancy category D, indicating evidence of risk to the fetus. It should be used during pregnancy only when the potential benefit justifies the risk. The drug is excreted in breast milk and may affect the nursing infant, so breastfeeding mothers should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Ligosan Slow Release. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

The primary alternative to doxycycline in periodontal therapy is minocycline, another tetracycline‑class antibiotic. Both share a similar mechanism of inhibiting protein synthesis, but minocycline often has a longer half‑life and may cause fewer gastrointestinal disturbances. However, doxycycline offers additional anti‑collagenase activity, which can be advantageous in managing tissue breakdown associated with periodontitis.

Ligosan Slow Release should be stored at temperatures below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture, excessive heat and direct light. Do not store in bathrooms or near kitchen appliances, and keep out of reach of children.

The product is intended for oral administration. Patients should swallow the tablets whole with a full glass of water, preferably with food to minimise gastrointestinal upset. If a specific periodontal protocol is required, the prescribing clinician will provide detailed instructions on timing relative to dental procedures.

Serious adverse events, although rare, include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, and hepatic dysfunction presenting as jaundice or elevated liver enzymes. Patients should seek immediate medical attention if they develop rash, blistering, persistent vomiting, yellowing of the skin or eyes, or signs of anaphylaxis.

Ligosan Slow Release is contraindicated in individuals with a known hypersensitivity to doxycycline, other tetracyclines, or any component of the formulation. It should also be avoided in pregnant women unless absolutely necessary, in nursing mothers without medical advice, and in patients with severe hepatic impairment or those younger than eight years of age.